Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China.
Kunming Children's Hospital, The Affiliated Children's Hospital of Kunming Medical University; Institute of Pediatric Disease Research in Yunnan, Kunming, People's Republic of China.
Emerg Microbes Infect. 2021 Dec;10(1):619-628. doi: 10.1080/22221751.2021.1899772.
Enterovirus A71 (EV-A71) inactivated vaccines have been widely inoculated among children in Kunming City after it was approved. However, there was a large-scale outbreak of Enteroviruses (EVs) infection in Kunming, 2018. The epidemiological characteristics of HFMD and EVs were analysed during 2008-2018, which are before and three years after EV-A71 vaccine starting to use. The changes in infection spectrum were also investigated, especially for severe HFMD in 2018. The incidence of EV-A71 decreased dramatically after the EV-A71 vaccine starting use. The proportion of non-CV-A16/EV-A71 EVs positive patients raised to 77.17-85.82%, while, EV-A71 and CV-A16 only accounted for 3.41-7.24% and 6.94-19.42% in 2017 and 2018, respectively. CV-A6 was the most important causative agent in all clinical symptoms (severe HFMD, HFMD, Herpangina and fever), accounting from 42.13% to 62.33%. EV-A71 only account for 0.36-2.05%. In severe HFMD, CV-A6 (62.33%), CV-A10 (11.64%), and CV-A16 (10.96%) were the major causative agent in 2018. EV-A71 inactivated vaccine has a good protective effect against EV-A71 and induced EVs infection spectrum changefully. EV-A71 vaccine has no or insignificant cross-protection effect on CV-A6, CV-A10, and CV-A16. Herein, developing 4-valent combined vaccines is urgently needed.
肠道病毒 A71(EV-A71)灭活疫苗获得批准后,已在昆明市儿童中广泛接种。然而,2018 年昆明市发生了大规模的肠道病毒(EVs)感染暴发。分析了 2008-2018 年手足口病和 EVs 的流行病学特征,这是在使用 EV-A71 疫苗之前和之后的三年。还调查了感染谱的变化,特别是 2018 年重症手足口病的变化。EV-A71 疫苗使用后,EV-A71 的发病率显著下降。非 CV-A16/EV-A71 EV 阳性患者的比例上升至 77.17%-85.82%,而 2017 年和 2018 年 EV-A71 和 CV-A16 仅分别占 3.41%-7.24%和 6.94%-19.42%。CV-A6 是所有临床症状(重症手足口病、手足口病、疱疹性咽峡炎和发热)的最重要病原体,占 42.13%-62.33%。EV-A71 仅占 0.36%-2.05%。在重症手足口病中,CV-A6(62.33%)、CV-A10(11.64%)和 CV-A16(10.96%)是 2018 年的主要病原体。EV-A71 灭活疫苗对 EV-A71 有很好的保护作用,并引起 EVs 感染谱的变化。EV-A71 疫苗对 CV-A6、CV-A10 和 CV-A16 没有或没有显著的交叉保护作用。因此,迫切需要开发 4 价联合疫苗。